Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

PURPOSE: Metastatic mucosal melanoma responds poorly to anti–programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Xinan, Yan, Xieqiao, Chi, Zhihong, Si, Lu, Cui, Chuanliang, Tang, Bixia, Li, Siming, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Zhou, Li, Kong, Yan, Dai, Jie, Wang, Kai, Tang, Xiongwen, Zhou, Huaning, Wu, Hai, Feng, Hui, Yao, Sheng, Flaherty, Keith T., Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839911/
https://www.ncbi.nlm.nih.gov/pubmed/31403867
http://dx.doi.org/10.1200/JCO.19.00210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839911/
https://www.ncbi.nlm.nih.gov/pubmed/31403867
http://dx.doi.org/10.1200/JCO.19.00210

Ejemplares similares